Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2013 2
2014 1
2016 2
2017 4
2018 1
2020 2
2021 7
2022 3
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, Winder T, Zukov R, Garbaos G, Gao S, Kuroda H, Ostoros G, Tran TV, You J, Lee KY, Antonuzzo L, Papai-Szekely Z, Akamatsu H, Biswas B, Spira A, Crawford J, Le HT, Aperghis M, Doherty GJ, Mann H, Fouad TM, Reck M; AEGEAN Investigators. Heymach JV, et al. Among authors: zukov r. N Engl J Med. 2023 Nov 2;389(18):1672-1684. doi: 10.1056/NEJMoa2304875. Epub 2023 Oct 23. N Engl J Med. 2023. PMID: 37870974 Clinical Trial.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Current and Prospective Protein Biomarkers of Lung Cancer.
Zamay TN, Zamay GS, Kolovskaya OS, Zukov RA, Petrova MM, Gargaun A, Berezovski MV, Kichkailo AS. Zamay TN, et al. Among authors: zukov ra. Cancers (Basel). 2017 Nov 13;9(11):155. doi: 10.3390/cancers9110155. Cancers (Basel). 2017. PMID: 29137182 Free PMC article. Review.
Development of DNA aptamers for visualization of glial brain tumors and detection of circulating tumor cells.
Kichkailo AS, Narodov AA, Komarova MA, Zamay TN, Zamay GS, Kolovskaya OS, Erakhtin EE, Glazyrin YE, Veprintsev DV, Moryachkov RV, Zabluda VV, Shchugoreva I, Artyushenko P, Mironov VA, Morozov DI, Khorzhevskii VA, Gorbushin AV, Koshmanova AA, Nikolaeva ED, Grinev IP, Voronkovskii II, Grek DS, Belugin KV, Volzhentsev AA, Badmaev ON, Luzan NA, Lukyanenko KA, Peters G, Lapin IN, Kirichenko AK, Konarev PV, Morozov EV, Mironov GG, Gargaun A, Muharemagic D, Zamay SS, Kochkina EV, Dymova MA, Smolyarova TE, Sokolov AE, Modestov AA, Tokarev NA, Shepelevich NV, Ozerskaya AV, Chanchikova NG, Krat AV, Zukov RA, Bakhtina VI, Shnyakin PG, Shesternya PA, Svetlichnyi VA, Petrova MM, Artyukhov IP, Tomilin FN, Berezovski MV. Kichkailo AS, et al. Among authors: zukov ra. Mol Ther Nucleic Acids. 2023 Mar 24;32:267-288. doi: 10.1016/j.omtn.2023.03.015. eCollection 2023 Jun 13. Mol Ther Nucleic Acids. 2023. PMID: 37090419 Free PMC article.
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S, Zukov R, Lazarev S, Makarova Y, Nechaeva M, Sakaeva D, Andreev A, Tarasova A, Fadeyeva N, Shustova M, Kuryshev I. Tjulandin S, et al. Among authors: zukov r. Eur J Cancer. 2021 May;149:222-232. doi: 10.1016/j.ejca.2021.02.030. Epub 2021 Apr 17. Eur J Cancer. 2021. PMID: 33872982 Free article. Clinical Trial.
[DNA aptamers selection for breast cancer].
Zamay GS, Belayanina IV, Zamay AS, Komarova MA, Krat AV, Eremina EN, Zukov RA, Sokolov AE, Zamay TN. Zamay GS, et al. Among authors: zukov ra. Biomed Khim. 2016 May;62(4):411-7. doi: 10.18097/PBMC20166204411. Biomed Khim. 2016. PMID: 27562994 Russian.
28 results